Q-omics provides the consensus-scored TNFSF18 profile across patient tissues and cancer cell-line models. TNFSF18 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TNFSF18 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TNFSF18 RNA expression shows 15,542 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, THCA, and UVM as cancer lineages where TNFSF18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFSF18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFSF18 survival associations across molecular data types. TNFSF18 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFSF18 RNA expression–survival associations across cancer types. High TNFSF18 expression shows unfavorable associations in LIHC, STAD and ACC, but favorable associations in SKCM, CESC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TNFSF18 RNA expression.
This table summarizes TNFSF18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TNFSF18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFSF18 shows lower tumor expression in KICH and higher tumor expression in THCA, KIRC, LUAD, STAD and HNSC. The THCA box plot shows higher TNFSF18 RNA expression in tumor versus normal tissue (log2 FC = +1.308, t-test p < 0.001).
This table shows molecular features associated with TNFSF18 in patient tissues and cancer cell lines. In patient samples, TNFSF18 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFSF18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
